Imaavy™ (nipocalimab-aahu) – New orphan drug approval
April 30, 2025 - Johnson & Johnson announced the FDA approval of Imaavy (nipocalimab-aahu), for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
Top